I agree w/ most all this analysis re Mayne Pharma $MYX.AX. I previously published my analysis of the security, and the road forward, here: https://t.co/t45ujgvAzP I have continued to build my position as I believe the stock remains significantly undervalued. I further believe the current lited structure is unsustainable, and the current BoD needs significant renewal. I remain focused on maximizing value for all shareholders.
View on X ↗